Skip to main content

Advertisement

SpringerLink
Log in

Frequency and prognostic impact of cachexia during drug treatment for unresectable advanced gastric cancer patients

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

Patients with unresectable advanced metastatic gastric cancer have a poor prognosis. This study examined the incidence and prognostic impact of cachexia during systemic drug treatment in such patients.

Methods

We enrolled patients with unresectable advanced gastric cancer who were treated with chemotherapy at Kochi Medical School from 2007 to 2020. Cancer cachexia was defined as > 5% weight loss or > 2% weight loss with a body mass index of < 20 kg/m2 within the past 6 months. Associations between clinicopathological parameters, cancer cachexia, and the overall survival were analyzed.

Results

Cancer cachexia occurred in 55.2% of 134 enrolled patients 6 months after chemotherapy. The incidence of cancer cachexia in initial unresectable gastric cancer was significantly higher than that in patients with recurrent cancer after curative resection. The median overall survival was significantly lower in the patients with cancer cachexia than in those without cancer cachexia at 6 months after starting systemic chemotherapy (13.7 months vs. 21.6 months, P = 0.032). Cancer cachexia at 6 months of starting treatment and CRP > 0.14 were identified as significantly associated with poor outcomes in a multivariate analysis (hazard ratio [HR] 1.339, 95% confidence interval [CI] 1.160–2.085, P = 0.019; HR 1.885, 95% CI 1.124–3.161, P = 0.016); respectively).

Conclusions

Cancer cachexia was frequently observed in unresectable advanced gastric cancer patients who received chemotherapy and was useful as a prognostic factor for the overall survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  Google Scholar 

  2. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–96.

    Article  Google Scholar 

  3. Bruggeman AR, Kamal AH, LeBlanc TW, Ma JD, Baracos VE, Roeland EJ. Cancer cachexia: beyond weight loss. J Oncol Pract. 2016;12:1163–71.

    Article  Google Scholar 

  4. Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle. 2015;6:287–302.

    Article  Google Scholar 

  5. Álvaro Sanz E, Garrido Siles M, Rey Fernández L, Villatoro Roldán R, Rueda Domínguez A, Abilés J. Nutritional risk and malnutrition rates at diagnosis of cancer in patients treated in outpatient settings: early intervention protocol. Nutrition. 2019;57:148–53.

    Article  Google Scholar 

  6. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.

    Article  CAS  Google Scholar 

  7. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.

    Article  Google Scholar 

  8. Caillet P, Liuu E, Raynaud Simon A, Bonnefoy M, Guerin O, Berrut G, et al. Association between cachexia, chemotherapy and outcomes in older cancer patients: a systematic review. Clin Nutr. 2017;36:1473–82.

    Article  Google Scholar 

  9. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.

    Article  CAS  Google Scholar 

  10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, ToGA Trial Investigators, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

    Article  CAS  Google Scholar 

  11. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.

    Article  CAS  Google Scholar 

  12. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol. 2009;10:1063–9.

    Article  CAS  Google Scholar 

  13. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, RAINBOW Study Group, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (Rainbow): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.

    Article  CAS  Google Scholar 

  14. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.

    Article  CAS  Google Scholar 

  15. Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437–48.

    Article  CAS  Google Scholar 

  16. Mitsunaga S, Kasamatsu E, Machii K. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Support Care Cancer. 2020;28:5271–9.

    Article  Google Scholar 

  17. Shibata M, Fukahori M, Kasamatsu E, Machii K, Hamauchi S. A retrospective cohort study to investigate the incidence of cachexia during chemotherapy in patients with colorectal cancer. Adv Ther. 2020;37:5010–22.

    Article  Google Scholar 

  18. Fukahori M, Shibata M, Hamauchi S, Kasamatsu E, Machii K. A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients. Support Care Cancer. 2021;29:341–8.

    Article  Google Scholar 

  19. Ock CY, Oh DY, Lee J, Kim TY, Lee KH, Han SW, et al. Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. Gastric Cancer. 2016;19:597–606.

    Article  CAS  Google Scholar 

  20. Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, et al. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer. 2015;23:1699–708.

    Article  Google Scholar 

  21. Minnella EM, Awasthi R, Loiselle SE, Agnihotram RV, Ferri LE, Carli F. Effect of exercise and nutrition prehabilitation on functional capacity in esophagogastric cancer surgery: a randomized clinical trial. JAMA Surg. 2018;153:1081–9.

    Article  Google Scholar 

  22. Muscaritoli M, Molfino A, Scala F, Christoforidi K, Manneh-Vangramberen IM, De Lorenzo F. Nutritional and metabolic derangements in Mediterranean cancer patients and survivors: the ECPC 2016 survey. J Cachexia Sarcopenia Muscle. 2019;10:517–25.

    Article  Google Scholar 

  23. Imamura H, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y, et al. Effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients: a randomized controlled clinical trial. Ann Surg Oncol. 2016;23:2928–35.

    Article  Google Scholar 

  24. Yu W, Seo BY, Chung HY. Postoperative body-weight loss and survival after curative resection for gastric cancer. Br J Surg. 2002;89:467–70.

    Article  CAS  Google Scholar 

  25. Aoyama T, Sato T, Maezawa Y, Kano K, Hayashi T, Yamada T, et al. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer. Int J Clin Oncol. 2017;22:476–83.

    Article  Google Scholar 

  26. Aoyama T, Maezawa Y, Yoshikawa T, Segami K, Kano K, Hayashi T, et al. Comparison of weight and body composition after gastrectomy between elderly and non-elderly patients with gastric cancer. In Vivo. 2019;33:221–7.

    Article  CAS  Google Scholar 

  27. Kubo H, Komatsu S, Ichikawa D, Kawaguchi T, Kosuga T, Okamoto K, et al. Impact of body weight loss on recurrence after curative gastrectomy for gastric cancer. Anticancer Res. 2016;36:807–13.

    CAS  PubMed  Google Scholar 

  28. Fein M, Fuchs KH, Thalheimer A, Freys SM, Heimbucher J, Thiede A. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg. 2008;247:759–65.

    Article  Google Scholar 

  29. Takayoshi K, Uchino K, Nakano M, Ikejiri K, Baba E. Weight loss during initial chemotherapy predicts survival in patients with advanced gastric cancer. Nutr Cancer. 2017;69:408–15.

    Article  CAS  Google Scholar 

  30. Chen XY, Zhang XZ, Ma BW, Li B, Zhou DL, Liu ZC, et al. A comparison of four common malnutrition risk screening tools for detecting cachexia in patients with curable gastric cancer. Nutrition. 2020;70: 110498. https://doi.org/10.1016/j.nut.2019.04.009.

    Article  PubMed  Google Scholar 

  31. Fujii H, Makiyama A, Iihara H, Okumura N, Yamamoto S, Imai T, et al. Cancer cachexia reduces the efficacy of nivolumab treatment in patients with advanced gastric cancer. Anticancer Res. 2020;40:7067–75.

    Article  CAS  Google Scholar 

  32. Lim HS, Lee B, Cho I, Cho GS. Nutritional and clinical factors affecting weight and fat-free mass loss after gastrectomy in patients with gastric cancer. Nutrients. 2020;12:1905.

    Article  Google Scholar 

  33. Davis JL, Selby LV, Chou JF, Schattner M, Ilson DH, Capanu M, et al. Patterns and predictors of weight loss after gastrectomy for cancer. Ann Surg Oncol. 2016;23:1639–45.

    Article  Google Scholar 

  34. Kuwada K, Kuroda S, Kikuchi S, Yoshida R, Nishizaki M, Kagawa S, et al. Clinical impact of sarcopenia on gastric cancer. Anticancer Res. 2019;39:2241–9.

    Article  Google Scholar 

  35. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85:495–522.

    Article  CAS  Google Scholar 

  36. Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019;125:4294–302.

    Article  CAS  Google Scholar 

  37. Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124:606–16.

    Article  CAS  Google Scholar 

  38. Zhou D, Zhang Y, Mamtawla G, Wan S, Gao X, Zhang L, et al. Iron overload is related to muscle wasting in patients with cachexia of gastric cancer: using quantitative proteome analysis. Med Oncol. 2020;37:113.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the contributions of our colleagues from the Department of Surgery, Kochi Medical School.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan

    Tsutomu Namikawa, Akira Marui, Keiichiro Yokota, Yuki Fujieda, Masaya Munekage, Sunao Uemura, Hiromichi Maeda, Hiroyuki Kitagawa & Kazuhiro Hanazaki

  2. Department of Human Health and Medical Sciences, Kochi Medical School, Kochi, Japan

    Michiya Kobayashi

Authors
  1. Tsutomu Namikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Marui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keiichiro Yokota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuki Fujieda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaya Munekage
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sunao Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiromichi Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyuki Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michiya Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuhiro Hanazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Namikawa.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Namikawa, T., Marui, A., Yokota, K. et al. Frequency and prognostic impact of cachexia during drug treatment for unresectable advanced gastric cancer patients. Surg Today 52, 1560–1567 (2022). https://doi.org/10.1007/s00595-022-02493-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-022-02493-9

Keywords

Search

Navigation